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Abstract
An increasing number of infections due to Pseudallescheria/Scedosporium species has been reported during the past decades, both in
immunocompromised and immunocompetent patients. Additionally, these fungi are now recognized worldwide as common agents of fungal
colonization of the airways in cystic ﬁbrosis patients, which represents a risk factor for disseminated infections after lung transplantation.
Currently six species are described within the Pseudallescheria/Scedosporium genus, including Scedosporium proliﬁcans and species of the
Pseudallescheria/Scedosporium apiospermum complex (i.e. S. apiospermum sensu stricto, Pseudallescheria boydii, Scedosporium aurantiacum,
Pseudallescheria minutispora and Scedosporium dehoogii). Precise identiﬁcation of clinical isolates at the species level is required because these
species differ in their antifungal drug susceptibility patterns. Matrix-assisted laser desorption ionization (MALDI)-time of ﬂight (TOF)/mass
spectrometry (MS) is a powerful tool to rapidly identify moulds at the species level. We investigated the potential of this technology to
discriminate Pseudallescheria/Scedosporium species. Forty-seven reference strains were used to build a reference database library. Proﬁles
from 3-, 5- and 7-day-old cultures of each reference strain were analysed to identify species-speciﬁc discriminating proﬁles. The database
was tested for accuracy using a set of 64 clinical or environmental isolates previously identiﬁed by multilocus sequencing. All isolates were
unequivocally identiﬁed at the species level by MALDI-TOF/MS. Our results, obtained using a simple protocol, without prior protein
extraction or standardization of the culture, demonstrate that MALDI-TOF/MS is a powerful tool for rapid identiﬁcation of Pseudallescheria/
Scedosporium species that cannot be currently identiﬁed by morphological examination in the clinical setting.
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Introduction
Pseudallescheria/Scedosporium species are ubiquitous ﬁlamen-
tous fungi commonly found in human-impacted environments,
particularly in highly polluted soils and waters [1]. These
thermotolerant moulds are opportunistic pathogens causing
severe and often fatal infections in immunocompromised
patients, such as bone marrow or solid organ transplant
recipients. They may also cause systemic mycoses in immu-
nocompetent individuals, including cerebral infections after
near-drowning [1–3]. Additionally, Pseudallescheria/Scedospori-
um are the second most important ﬁlamentous fungi, after
Aspergillus fumigatus, involved in the colonization of the
respiratory tract of patients with cystic ﬁbrosis (CF) [4–6].
In these patients, a chronic colonization of the airways by
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Scedosporium proliﬁcans or species of the Pseudallescheria boydii/
Scedosporium apiospermum complex is a major risk for invasive
infection after lung transplantation. Indeed, these fungi can
disseminate in immunocompromised patients and exhibit low
susceptibility to current antifungal drugs [7].
Until recently, only two clinically important Scedosporium
species were described: Scedosporium proliﬁcans and Scedospo-
rium apiospermum (previously considered as being the P. boydii
anamorph). However, thanks to multilocus sequencing (MLS)
along with morphological and physiological studies, S. apio-
spermum is now considered as a distinct species (Pseudalle-
scheria apiosperma being its teleomorph) and three new species
are described within the P. boydii/S. apiospermum complex (i.e.
Scedosporium aurantiacum, Scedosporium dehoogii and Pseudalle-
scheria minutispora) [8–10]. S. apiospermum, P. boydii and S. au-
rantiacum are the most common human pathogens of this
species complex, P. minutispora and S. dehoogii being only
described in few patients [11,12] (F. Morio et al., unpublished
observation). The accurate identiﬁcation of clinical isolates at
the species level is of overall importance because the antifungal
susceptibility can differ between species [13]. However, due to
the lack of speciﬁc phenotypic characteristics and the high
degree of morphological diversity, the identiﬁcation at the
species level of the members of the Pseudallescheria/Scedospo-
rium complex on the basis of morphology is challenging [12].
Matrix-assisted laser desorption ionization-time of ﬂight/
mass spectrometry (MALDI-TOF/MS) is now increasingly used
for routine phenotypic identiﬁcation of bacterial and yeast
species [14–16]. Moreover, recent studies have reported the
efﬁciency of MALDI-TOF/MS for rapid identiﬁcation of moulds
[17,18]. Nevertheless, an exhaustive mass spectral library is
still lacking for the identiﬁcation of Pseudallescheria/Scedospo-
rium species [19].
Here, we developed a speciﬁc database for the identiﬁcation
of Pseudallescheria/Scedosporium species by MALDI-TOF/MS.
This database was then evaluated using a large number of
clinical and environmental isolates. Our ﬁndings highlight that
MALDI-TOF/MS is a reliable, fast and accurate method for the
routine identiﬁcation of S. proliﬁcans and of species belonging
to the P. boydii/S. apiospermum complex.
Materials and Methods
Strains and culture conditions
This study was conducted using two sets of strains or isolates.
The ﬁrst set, used to build the reference database, consisted of
47 reference strains belonging to the following clinically
relevant Pseudallescheria/Scedosporium species: P. boydii
(n = 20), S. apiospermum (n = 11), S. aurantiacum (n = 4),
P. minutispora (n = 2), S. dehoogii (n = 5) and S. proliﬁcans
(n = 5) (Table 1). The second set, including 64 clinical
(n = 57) or environmental isolates (n = 7) obtained from
different hospitals in France, was used to evaluate the new
Pseudallescheria/Scedosporium MALDI-TOF database engi-
neered in this study. Isolates were previously identiﬁed by
conventional methods, including macroscopic and microscopic
morphological investigations. Species identiﬁcation was also
performed by multilocus sequence analysis (considered as the
reference standard) relying on PCR ampliﬁcation and sequenc-
ing of the internal transcribed spacer (ITS) regions 1 and 2 of
the ribosomal RNA genes, one region in the calmodulin gene
(CAL) and two regions within the beta-tubulin gene (TUB and
BT2), as previously described [10].
All reference strains and tested isolates were grown at 30°C
from 3 to 7 days on Sabouraud dextrose agar plates containing
chloramphenicol and gentamicin (BD BBLTM StackerTM Plates,
Becton-Dickinson, Heidelberg, Germany).
MALDI-TOF/MS
(1) Sample preparation. All strains or isolates used to engineer
and validate the database were grown at 30°C and checked
daily for maturation (sporulation and mycelium development).
The surface of the colonies was scraped using a sterile swab
and the fungal mass was mixed with 1.5 lL of formic acid (70%
vol/vol) previously deposited on a target plate (Andromas,
Paris, France). After drying at room temperature, 1 lL of
matrix solution HCCA (saturated solution of a-cyano-4-hy-
droxycinnaminic acid, 50% acetonitrile, 2.5% triﬂuoroacetic
acid) was added to each spot, and was allowed to cocristallize
with the sample. Strains used for the database construction
were deposited in 10 replicates while isolates used to validate
the database were deposited in two replicates.
(2) Instrument type. All samples were processed using the
Andromas system. This system includes a mass spectrometry
apparatus combined with control software and various data-
bases for identiﬁcation of bacteria, yeasts or ﬁlamentous fungi
[20–22]. For each sample, positive ions were extracted with an
accelerating voltage of 20 kV in linear mode. The spectra were
analysed and compared over an m/z range of 3000–20 000
with the Andromas software.
(3) Data analysis. For the Scedosporium database construction,
the Andromas software recorded the number of peaks
common to the ten spectra obtained for the different
reference strains tested and deﬁned species-speciﬁc spectral
ﬁngerprints. For each isolate used for the validation of the
database, only peaks with an intensity higher than 0.1 were
considered and their proﬁles were compared with the
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species-speciﬁc spectral ﬁngerprints, taking into account
possible variations in the m/z value of  10 m/z [18,22]. The
percentage of common peaks was obtained with the following
formula: 100 9 (number of peaks common between the peaks
of the tested isolate and the peaks of the species-speciﬁc
spectral ﬁngerprint/total number of peaks speciﬁc to the
species-speciﬁc spectral ﬁngerprint). Species identiﬁcation for
a tested isolate was considered acceptable when ≥ 70% of the
peaks were shared with the reference strains in the database.
Only the ﬁrst and second best species level matches were
considered. A difference of at least 10% between the ﬁrst and
the second match was required. When the identiﬁcation was
not acceptable (i.e. < 70% of peaks shared with the reference
strains or < 10% difference between the ﬁrst and second
matches), a second run was performed and the results were
analysed in a similar manner [18,22]. An external control
(Pseudomonas aeruginosa) was used to validate the calibration
for each experiment [21].
Results
Reference database
The database for Pseudallescheria/Scedosposium species identi-
ﬁcation was engineered using a previously described strategy
[18,22]. A set of reference strains belonging to the clinically
relevant Pseudoallescheria/Scedosporium species described in
Materials and Methods was used to construct the mass
spectral database. The MALDI-TOF/MS spectra obtained from
10 different runs were analysed for each reference strain. The
majority of ions detected was in the range of 4000–14 000 Da.
For each reference strain, only peaks with a relative intensity >
TABLE 1. Reference strains used to establish the matrix-assisted laser desorption ionization-time of ﬂight/mass spectrometry
database (n = 47)
Species Strain number
Geographical
origin
Isolation
date (d/m/y)
Clinical
context GenBank accession number
Pseudallescheria boydii IHEM 23566 Angers 11/01/2005 Cystic ﬁbrosis ITS: JQ690902; CAL: JQ691065; BT2: JQ690955; TUB: JQ691008
Pseudallescheria boydii IHEM 23582 Angers 03/06/2006 Cystic ﬁbrosis ITS: JQ690905; CAL: JQ691068; BT2: JQ690958; TUB: JQ691011
Pseudallescheria boydii 40504117/1 Angers 24/06/2005 Cystic ﬁbrosis ITS: JQ690906; CAL: JQ691069; BT2: JQ690959; TUB: JQ691012
Pseudallescheria boydii IHEM 23569 Angers 09/08/2007 Cystic ﬁbrosis ITS: JQ690907; CAL: JQ691070; BT2: JQ690960; TUB: JQ691013
Pseudallescheria boydii IHEM 14354 Giens 19/01/1998 Cystic ﬁbrosis ITS: JQ690910; CAL: JQ691073; BT2: JQ690963; TUB: JQ691016
Pseudallescheria boydii IHEM 13943 Giens 23/04/1992 Cystic ﬁbrosis ITS: JQ690912; CAL: JQ691075; BT2: JQ690965; TUB: JQ691018
Pseudallescheria boydii IHEM 23567 Caen 14/04/2006 Cystic ﬁbrosis ITS: JQ690915; CAL: JQ691078; BT2: JQ690968; TUB: JQ691021
Pseudallescheria boydii IHEM 14361 Tours 16/02/1998 Cystic ﬁbrosis ITS: JQ690919; CAL: JQ691082; BT2: JQ690972; TUB: JQ691025
Pseudallescheria boydii IHEM 23574 Angers 09/05/2007 Cystic ﬁbrosis ITS: JQ690920; CAL: JQ691083; BT2: JQ690973; TUB: JQ691026
Pseudallescheria boydii IHEM 15466 Giens 09/11/1998 Cystic ﬁbrosis ITS: JQ690922; CAL: JQ691085; BT2: JQ690975; TUB: JQ691028
Pseudallescheria boydii IHEM 23579 Giens 07/04/2008 Cystic ﬁbrosis ITS: JQ690932; CAL: JQ691095; BT2: JQ690985; TUB: JQ691038
Pseudallescheria boydii 80331879 Toulouse 13/08/2008 Cystic ﬁbrosis ITS: JQ690935; CAL: JQ691098; BT2: JQ690988; TUB: JQ691041
Pseudallescheria boydii IHEM 23581 Toulouse 04/06/2008 Cystic ﬁbrosis ITS: JQ690939; CAL: JQ691102; BT2: JQ690992; TUB: JQ691045
Pseudallescheria boydii IHEM 23828 Giens 17/04/2009 Cystic ﬁbrosis ITS: JQ690940; CAL: JQ691103; BT2: JQ690993; TUB: JQ691046
Pseudallescheria boydii IHEM 23825 Giens 10/11/2008 Cystic ﬁbrosis ITS: JQ690942; CAL: JQ691105; BT2: JQ690995; TUB: JQ691048
Pseudallescheria boydii IHEM 23832 Giens 03/09/2008 Cystic ﬁbrosis ITS: JQ690943; CAL: JQ691106; BT2: JQ690996; TUB: JQ691049
Pseudallescheria boydii IHEM 23826 Angers 26/11/2009 Cystic ﬁbrosis ITS: JQ690944; CAL: JQ691107; BT2: JQ690997; TUB: JQ691050
Pseudallescheria boydii IHEM 23834 Angers 03/04/2008 Cystic ﬁbrosis ITS: JQ690947; CAL: JQ691110; BT2: JQ691000; TUB: JQ691053
Pseudallescheria boydii 100152417-01 Giens 24/02/2010 Cystic ﬁbrosis ITS: JQ690948; CAL: JQ691111; BT2: JQ691001; TUB: JQ691054
Pseudallescheria boydii IHEM 23827 Rouen 01/08/2008 Cystic ﬁbrosis ITS: JQ690949; CAL: JQ691112; BT2: JQ691002; TUB: JQ691055
Scedosporium apiospermum IHEM 14268 Giens 08/01/1998 Cystic ﬁbrosis ITS: JQ690913; CAL: JQ691076; BT2: JQ690966; TUB: JQ691019
Scedosporium apiospermum IHEM 14766 Tours 11/08/1998 Cystic ﬁbrosis ITS: JQ690916; CAL: JQ691079; BT2: JQ690969; TUB: JQ691022
Scedosporium apiospermum IHEM 15150 Giens 22/09/1998 Cystic ﬁbrosis ITS: JQ690918; CAL: JQ691081; BT2: JQ690971; TUB: JQ691024
Scedosporium apiospermum IHEM 23576 Angers 22/04/2002 Cystic ﬁbrosis ITS: JQ690924; CAL: JQ691087; BT2: JQ690977; TUB: JQ691030
Scedosporium apiospermum IHEM 23577 Paris (Necker) 23/01/2003 Cystic ﬁbrosis ITS: JQ690926; CAL: JQ691089; BT2: JQ690979; TUB: JQ691032
Scedosporium apiospermum IHEM 13940 Angers 23/12/1991 Cystic ﬁbrosis ITS: JQ690928; CAL: JQ691091; BT2: JQ690981; TUB: JQ691034
Scedosporium apiospermum IHEM 13942 Giens 15/06/1992 Cystic ﬁbrosis ITS: JQ690929; CAL: JQ691092; BT2: JQ690982; TUB: JQ691035
Scedosporium apiospermum IHEM 23580 Toulouse 06/05/2008 Cystic ﬁbrosis ITS: JQ690934; CAL: JQ691097; BT2: JQ690987; TUB: JQ691040
Scedosporium apiospermum 100353188-01 Rouen 18/07/2007 Cystic ﬁbrosis ITS: JQ690936; CAL: JQ691099; BT2: JQ690989; TUB: JQ691042
Scedosporium apiospermum IHEM 23824 Giens 21/07/2009 Cystic ﬁbrosis ITS: JQ690941; CAL: JQ691104; BT2: JQ690994; Tub: JQ691047
Scedosporium apiospermum IHEM 23836 Giens 17/02/2010 Cystic ﬁbrosis ITS: JQ690946; CAL: JQ691109; BT2: JQ690999; TUB: JQ691052
Scedosporium aurantiacum 40503256 Angers 23/05/2005 Cystic ﬁbrosis ITS: JQ690903; CAL: JQ691066; BT2: JQ690956; TUB: JQ691009
Scedosporium aurantiacum 1007M230067 Paris (Necker) 23/07/2010 Cystic ﬁbrosis NA
Scedosporium aurantiacum IHEM 23578 Tours 06/05/2008 Cystic ﬁbrosis ITS: JQ690931; CAL: JQ691094; BT2: JQ690984; TUB: JQ691037
Scedosporium aurantiacum 7070660 Rouen 18/07/2007 Cystic ﬁbrosis ITS: JQ690938; CAL: JQ691101; BT2: JQ690991; TUB: JQ691044
Scedosporium dehoogii 1107M210058 Nantes 02/04/2009 Osteitis NA
Scedosporium dehoogii UA 110349226-01/1 Angers 20/10/2011 Environment TUB: KC779445
Scedosporium dehoogii UA110349255-01/2 Angers 04/11/2011 Environment TUB: KC779449
Scedosporium dehoogii UA110349310-01 Angers 10/11/2011 Environment TUB: KC779464
Scedosporium dehoogii UA110354504-01/3 Angers 29/11/2011 Environment TUB: KC779476
Scedosporium proliﬁcans 680 Paris (Cochin) NA NA NA
Scedosporium proliﬁcans IHEM 22175 Angers 07/03/2006 Cystic ﬁbrosis ITS: EF469853, EF469852
Scedosporium proliﬁcans IHEM 22178 Angers 01/08/2006 Cystic ﬁbrosis ITS: EF469856, EF469857
Scedosporium proliﬁcans IHEM 22179 Angers 17/11/2006 Cystic ﬁbrosis ITS: EF469859
Scedosporium proliﬁcans IHEM 14076 Angers 17/09/1994 Cystic ﬁbrosis ITS: AM887701
Pseudallescheria minutispora IHEM 23572 Angers 08/03/2006 Cystic ﬁbrosis ITS: JQ690914; CAL: JQ691077; BT2: JQ690967; TUB: JQ691020
Pseudallescheria minutispora IHEM 23837 Angers 06/05/2003 Cystic ﬁbrosis ITS: JQ690945; CAL: JQ691108; BT2: JQ690998; TUB: JQ691051
ITS, internal transcribed spacer regions 1 and 2 of ribosomal RNA genes; CAL, calmodulin gene; BT2 and TUB, two distinct regions in the beta-tubulin gene; NA, not available.
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0.1 and constantly present in all spectra obtained for a given
species were considered. The standard deviation for each
conserved peak did not exceed a 6 m/z value. As some
differences were observed in the spectra obtained from young
and mature colonies within the same species, proﬁles from
colonies at different incubation times (3-, 5- and 7-day-old
cultures) were analysed for each reference strain. Although
some of the species studied shared common peaks, the whole
set of peaks, called the spectral ﬁngerprint, was speciﬁc for
each reference strain. Figure 1 shows an example of the
spectral ﬁngerprints obtained for the six Pseudoallescheria/
Scedosporium species.
Validation of the database
We next aimed at determining whether the above database
could be used for routine identiﬁcation of Pseudallescheria/
Scedosporium species. The database was tested blindly with a
set of 57 clinical (19 P. boydii, 23 S. apiospermum, six S. auran-
tiacum, three P. minutispora, one S. dehoogii and ﬁve S. proliﬁ-
cans) and seven environmental (six S. dehoogii and one
P. minutispora) isolates.
The results of MALDI-TOF/MS identiﬁcation were com-
pared with those obtained by multilocus sequence analysis
(Table 2). Both methods were in perfect agreement, because
our MALDI-TOF/MS strategy allowed correct species identi-
ﬁcation for all the isolates tested (64/64).
Discussion
This study shows that our MALDI-TOF/MS system is a rapid
and powerful technique for the accurate identiﬁcation of
clinically relevant Pseudallescheria/Scedosporium species. Indeed,
the Andromas system combined with the newly constructed
database was able to discriminate all isolates tested with a high
rate (100%) of correct identiﬁcation at the species level.
The taxonomy of Scedosporium and Peudallescheria species is
highly complex [23]. In addition to the well-known S. proliﬁ-
cans, ﬁve other species belonging to the P. boydii/S. apiosper-
mum complex have recently been described: S. apiospermum,
P. boydii, S. aurantiacum, P. minutispora and S. dehoogii [9,10].
Species of this complex are morphologically indistinguishable
from each other on the basis of simple phenotypic traits tests
commonly used in the laboratory. Our results show that the
Andromas MALDI-TOF/MS system allows precise identiﬁca-
tion of these sibling species using a very simple and rapid
experimental procedure without laborious sample preparation
steps, such as subculture or prior protein extraction. The mass
spectral database developed in this study includes species-spe-
ciﬁc spectral ﬁngerprints from colonies of varying age (3-, 5-
and 7-day-old cultures). Consequently, precise species identi-
ﬁcation can be performed regardless of the maturity of the
colony. Altogether, the identiﬁcation of Peudallescheria/Scedos-
porium species by MALDI-TOF/MS offers several advantages
over the conventional methods currently used for the
identiﬁcation of this group of ﬁlamentous fungi.
Our system also presents advantages compared with the
MLS strategy, considered as the reference standard for the
identiﬁcation of species of Pseudallescheria/Scedosporium.
Indeed, the MLS strategy requires experienced staff, and is
expensive and time-consuming, taking several days for DNA
extraction, PCR ampliﬁcation of the target genes and sequenc-
ing [24]. Another molecular approach, recently developed, is
the semi-automated rep-PCR that is based on PCR ampliﬁca-
tion of different sized repetitive sequences dispersed through-
out the genome. This method is easy to use, provides
same-day results and has proven to be a powerful tool to
track the source and spread of microbial infection, allowing
quick and accurate differentiation of microbial isolates at the
subspecies and strain level. Regarding Pseudallescheria/Scedos-
porium species, this system showed a high degree of repro-
ducibility, discriminating species of the P. boydii/S. apiospermum
complex from other ﬁlamentous fungi, including S. proliﬁcans
[24]. However, rep-PCR could not discriminate P. boydii
isolates from those of S. apiospermum, perhaps due to the
frequent occurrence of polymorphisms and the high recom-
bination rate in the genomes of these sibling species.
The accurate identiﬁcation to the species level of Scedos-
porium/Pseudallescheria species is also of clinical importance
because of the inter-species variability in both virulence and in
vitro susceptibility to antifungal agents [13,25,26]. Indeed,
whereas S. apiospermum and P. boydii have similar antifungal
susceptibility patterns, S. aurantiacum, S. proliﬁcans and S. de-
hoogii present notably different patterns. In particular, S. pro-
liﬁcans and S. aurantiacum are less susceptible than other
species to all current systemic antifungal drugs [13]. These
species are also more virulent than the others in experimental
models and the mortality rate associated with S. proliﬁcans
infection is particularly high [26]. It is therefore important to
precisely and rapidly differentiate these two species from the
other Pseudallescheria and Scedosporium species.
One limitation of our study concerns the uncommon
species that are S. dehoogii, S. proliﬁcans and P. minutispora.
Indeed, the number of reference strains included in the
database was limited, which may affect the identiﬁcation
performance. Likewise, few clinical isolates of these species
were available for the validation of the database.
In conclusion, MALDI-TOF/MS represents a powerful tool
to discriminate Pseudallescheria/Scedosporium species and could
replace molecular methods for routine identiﬁcation in clinical
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laboratories. It should help to enable the early adaptation of
antifungal therapy and to avoid microbiological therapeutic
failure in case of infection due to species with an innate
resistance to antifungal drugs. In addition, we believe that
MALDI-TOF/MS technology will provide a real opportunity to
improve our knowledge of the epidemiology and ecology of
clinically relevant Pseudallescheria/Scedosporium species by
allowing fast and accurate species identiﬁcation. Ultimately,
from a better knowledge of the reservoir of these fungi, it
should be possible to implement prophylactic measures aiming
FIG. 1. Matrix-assisted laser desorption ionization-time of ﬂight/mass spectrometry reference spectra of clinically relevant Pseudallescheria/
Scedosporium species.
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 929–935
CMI Sitterle et al. MALDI-TOF/MS identiﬁcation of Scedosporium spp. 933
to prevent the colonization of the airways by these opportu-
nistic pathogens in CF patients.
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